Uprosertib

DRUG4 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaHematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid NeoplasmLocally Advanced Melanoma

Phase 1

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

CompletedNCT01902173

National Cancer Institute (NCI)Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma +6

Start: 2013-10-08End: 2023-12-23Updated: 2025-01-14

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

CompletedNCT01935973

National Cancer Institute (NCI)Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma +3

Start: 2013-09-30End: 2015-09-08Updated: 2020-10-14

Phase 2

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Active, not recruitingNCT01979523

National Cancer Institute (NCI)Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7

Start: 2013-11-21End: 2026-07-02Updated: 2026-04-03

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT01989598

National Cancer Institute (NCI)Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma

Start: 2013-10-30End: 2020-09-28Updated: 2022-03-02

Related Papers

A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with <i>BRAF</i>‐mutated cancers

Cancer2024-01-239 citations

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.

2019-04-1867 citations

SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).

Journal of Clinical Oncology2017-05-206 citations

A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma.

Journal of Clinical Oncology2016-05-2054 citations